NASDAQ
0.83USD
-0.04 (-4.76%)
We have scored 3 news catalysts on Marker Therapeutics, Inc. (MRKR) over the past 12 months. The biggest single-day move next to one of them came Nov 17, 2026, when MRKR closed −4.8%: “MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Lags Revenue Estimates”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
13.8M
P/E
—
EPS
—
Beta
1.62
52W range
0.8201-2.46
Day range
0.82–0.91
Open
0.86
Prev close
0.87
Volume
135.6K
Avg volume
98.3K
Dividend
0.00
IPO
2002-07-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Marker Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MRKR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.